Check out your Company Bowl for anonymous work chats.
Moderna to Provide Business and Pipeline Updates at the 2020 J.P. Morgan Healthcare Conference
Read our most recent "People Profile" about Joe Cabral, a Moderna alumnus!
In October, we welcomed the Propionic Acidemia Foundation president & the Cotrina/Lopez family, whose oldest son was diagnosed w/ #propionicacidemia, to share their stories at a Town Hall mtg. We’re committed to learning directly from patients & advocates who inspire us every day! #mRNA #rarediseases http://glassdoor.com/slink.htm?key=vMRM4
Moderna Named Top Employer by Science for Fifth Consecutive Year http://glassdoor.com/slink.htm?key=vMRMi
http://glassdoor.com/slink.htm?key=vMcGF
We had a great time celebrating our annual Moderna Family Day at the "Lawn on D" in Boston in August!
Moderna Provides Mid-Year Corporate Update CAMBRIDGE, Mass., July 11, 2018 — Moderna Therapeutics, a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create transformative medicines for patients, today provided updates on its portfolio of development candidates and progress on its 2018 priorities. Moderna now has 21 mRNA development candidates in its pipeline with 10 in clinical development, including one program in Phase 2 and nine programs in Phase 1. The Company remains focused on executing against its pre-clinical and clinical development pipeline; introducing new rare disease and prophylactic vaccine candidates in areas of unmet need; continuing investment in its mRNA development platform; and opening the company’s new GMP clinical development manufacturing plant. Key updates from the first half of the year include: A Phase 1 study of MRK-V171, an undisclosed infectious disease candidate being co-developed with Merck, met its primary and secondary objectives. Initiation of a Phase 1 study for NCI-4650, the second personalized
Congratulations to the Moderna soccer team for winning their second consecutive title with the Boston Ski and Sports Club!
